Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) will be releasing its earnings data after the market closes on Monday, November 20th. Analysts expect Enanta Pharmaceuticals to post earnings of ($2.11) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Enanta Pharmaceuticals Trading Up 5.1 %
Shares of ENTA opened at $9.13 on Friday. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $62.06. The stock’s 50 day moving average is $10.14 and its two-hundred day moving average is $17.41. The firm has a market cap of $192.23 million, a P/E ratio of -1.45 and a beta of 0.48.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sei Investments Co. purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at $535,000. AQR Capital Management LLC raised its position in Enanta Pharmaceuticals by 608.1% in the third quarter. AQR Capital Management LLC now owns 137,776 shares of the biotechnology company’s stock valued at $1,539,000 after purchasing an additional 118,320 shares during the period. Tower Research Capital LLC TRC raised its position in Enanta Pharmaceuticals by 207.2% in the third quarter. Tower Research Capital LLC TRC now owns 6,224 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 4,198 shares during the period. Qube Research & Technologies Ltd raised its position in Enanta Pharmaceuticals by 149.3% in the third quarter. Qube Research & Technologies Ltd now owns 113,672 shares of the biotechnology company’s stock valued at $1,270,000 after purchasing an additional 68,076 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at $115,000. Institutional investors and hedge funds own 94.99% of the company’s stock.
Analysts Set New Price Targets
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
- Five stocks we like better than Enanta Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 large caps with red hot RSIs with upside
- How and Why to Invest in Oil Stocks
- Johnson Controls International: Nothing but upside for investors
- How to Invest in Semiconductors
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.